The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.
Site Search
Showing 391 - 400 of 411 results
News
|
Aug. 31, 2012
|
2 min read
News
|
May 25, 2012
|
2 min read
News
|
Oct. 25, 2012
|
2 min read
News
|
April 19, 2012
|
3 min read
News
|
Dec. 21, 2012
|
3 min read
News
|
Aug. 31, 2012
|
1 min read
News
|
Feb. 6, 2017
|
1 min read
On Aug. 27, leaders from the Cystic Fibrosis Foundation, along with several people from the CF community, participated in a virtual public meeting hosted by the Institute for Clinical and Economic Review to provide insights and expertise on the value of CFTR modulators.
News
|
Sept. 27, 2020
|
3 min read
The Board’s review put Coloradans with CF at the center of the discussion, helping to preserve vital access to Trikafta®.
News
|
Dec. 8, 2023
|
2 min read
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
News
|
Jan. 5, 2024
|
2 min read